Narrative review highlights treatment toxicity and resistance in nonimmune travelers, suggesting management strategies and genomic surveillance.
Several factors (e.g. lack of prior immunity, older age, overweight, comorbidities, and comedication) distinguish travelers from people residing in malaria-endemic areas. Yet, current uniform treatment recommendations across settings do not address many considerations that predominantly affect nonimmune travelers with malaria. This population may also be more vulnerable to complications of malaria as reduced susceptibility to key antimalarials spreads. We propose specific adaptations to the management of malaria in travelers, with a focus on structured clinical follow-up to detect toxicity and failure, and on systematic genomic surveillance in concert with existing initiatives in endemic countries.
No takes yet. Share an insight, caveat, or question.
Bottieau et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: